Kymera Therapeutics Q3 2026 Results: Net Loss of $132M, Loss Widens
Kymera Therapeutics reported collaboration revenue of $99.4 million for the nine months ended September 30, 2026, a significant increase from $36.3 million in the prior year. Despite this, the company recorded a net loss of $262.4$ million for the period due to rising research and development expenses, which reached $346.2 million.
- Key figure
- Net loss $132M